22 Sep 2026
By SNI Clinical Research
FDA Launches Expedited IND Pilot for First-in-Human Clinical Trials

FDA Launches Expedited IND Pilot for First-in-Human Clinical Trials

Regulatory Updates, , , ,
On September 15, 2026, the U.S. Food and Drug Administration (FDA) announced the final design of its Expedited Investigational New Drug (IND) Pilot Program and began accepting applications for the initial cohort.  The voluntary pilot is designed to test whether closer collaboration among drug sponsors, Qualified Research Institutions (QRIs), and FDA can shorten the path from IND-enabling development to a first-in-human Phase 1 clinical trial. Its defining feature is a rolling pre-IND review process that allows FDA to review completed, discipline-specific components before the sponsor submits the final IND application.  The opportunity is significant but narrow. FDA expects to select…
Read More
22 Sep 2026
By SNI Clinical Research
Health Canada Introduces Interim Policy to Modernize the Clinical Trial Framework

Health Canada Introduces Interim Policy to Modernize the Clinical Trial Framework

Regulatory Updates, ,
On September 14, 2026, Health Canada published an interim policy intended to support more flexible and efficient clinical trial conduct in Canada. The policy advances three targeted elements of the federal Clinical Trials Modernization initiative while the regulator finalizes its proposed Clinical Trials Regulations.  The interim policy does not amend the existing regulations. Rather, Health Canada is applying specified interim interpretations of the current framework while the proposed Clinical Trials Regulations are being finalized.  Health Canada has also updated the Clinical Trial Site Information (CTSI) form instructions to reflect these interim interpretations, including the revised approach to qualified investigators and…
Read More
16 Sep 2026
By SNI Clinical Research
Cosmetic Testing Requirements in Canada: A Guide for Skincare Brands

Cosmetic Testing Requirements in Canada: A Guide for Skincare Brands

Regulatory Requirements, , , , , , , ,
Canada does not prescribe a single set of laboratory or clinical tests that every cosmetic must complete before sale. Instead, manufacturers and importers of skincare brands are responsible for ensuring that their cosmetics are safe under the applicable conditions of use and that their marketing claims are properly supported. The testing and evidence needed will therefore depend on the formulation, intended use, product claims, and information already available. For manufacturers and importers, the distinction has practical consequences. A supplier dossier, a favourable patch test and a completed Cosmetic Notification Form (CNF) each serve a different purpose; none should be treated…
Read More
26 Aug 2026
By SNI Clinical Research
Health Canada Begins Phased Implementation of ICH Q12 and Q14: What Sponsors Should Know

Health Canada Begins Phased Implementation of ICH Q12 and Q14: What Sponsors Should Know

Health Canada Updates, , ,
This article examines Health Canada’s phased implementation of ICH Q12 and ICH Q14 and its implications for pharmaceutical quality, CMC development, analytical procedures, and post-approval change management in Canada. It explains the initial application of Post-Approval Change Management Protocols to biologic and Schedule C drugs regulated by the Biologic and Radiopharmaceutical Drugs Directorate (BRDD), clarifies that Established Conditions are not yet included, and outlines how sponsors can begin preparing for broader implementation. Introduction Health Canada has announced the interim implementation of ICH Q12: Technical and Regulatory Considerations for Pharmaceutical Product Lifecycle Management, along with implementation of ICH Q14: Analytical Procedure Development. This…
Read More
10 Jul 2026
By SNI Clinical Research
Clinical Evidence for Skincare Products: Claims, Trial Design, Endpoints, and Regulatory Impact in Canada and the U.S.

Clinical Evidence for Skincare Products: Claims, Trial Design, Endpoints, and Regulatory Impact in Canada and the U.S.

Clinical Research Insights
Clinical evidence in skincare supports regulatory defensibility, claim substantiation, and commercial credibility across Canada and the United States. As skincare products move across categories such as cosmetics, sunscreens, antiperspirants, antibacterial products, wound care, and oral skin health supplements, trial design, endpoint selection, and participant criteria become critical to how claims are supported and positioned in-market. Introduction Skincare has become an increasingly evidence-driven and commercially competitive category across Canada and the United States. As brands pursue stronger performance claims, broader market access, and greater scientific credibility, human clinical data has become central to claim substantiation, regulatory strategy, and product differentiation. Clinical…
Read More
28 May 2026
By SNI Clinical Research
How Effective Recruitment Supports Clinical Trial Execution

How Effective Recruitment Supports Clinical Trial Execution

Clinical Research Insights, , , , , , , , ,
A clinical trial is only as strong as its ability to recruit the right participants. While study design, protocol development, and data collection are central to clinical research, participant recruitment is often the point at which timelines, feasibility, and study quality are tested most directly. A trial cannot move forward without willing participants who meet the appropriate eligibility criteria, and even a well-designed study can lose momentum if recruitment is not planned with the same level of strategy and discipline as the trial itself.  Recruitment Is More Than Broad Outreach  Recruitment is not simply about reaching a large audience. It is about…
Read More
14 Apr 2026
By SNI Clinical Research
Rinse-Off Cosmetic Testing: Key Study Considerations for Brands 

Rinse-Off Cosmetic Testing: Key Study Considerations for Brands 

Clinical Research Insights, , , , , , , , ,
The cosmetic category encompasses a broad range of product formats, with leave-on and rinse-off formulations representing two of the most fundamental functional sub-categories. The distinction between these formats is important not only for end users, but also for the research, formulation, and product development teams responsible for designing new products or optimizing existing systems.  At the formulation stage, duration of exposure becomes a critical scientific and technical variable, directly influencing ingredient selection, delivery strategy, and the balance between functional excipients and performance-driven actives.   This article explores the key scientific and commercial considerations involved in developing or optimizing rinse-off cosmetic products, including which brands benefit…
Read More
19 Feb 2026
By SNI Clinical Research
Skincare Clinical Trials: How Efficacy Data Substantiates Cosmetic Claims 

Skincare Clinical Trials: How Efficacy Data Substantiates Cosmetic Claims 

Clinical Research Insights, , , , , , , ,
Skincare efficacy clinical trials are structured human studies designed to determine whether a finished topical formulation delivers measurable and reproducible cosmetic benefits under defined conditions of use. These studies evaluate predefined endpoints such as wrinkle depth, transepidermal water loss (TEWL), hydration levels, lesion counts, pigment intensity, firmness, and barrier integrity and related-parameters over specified time points.  Depending on the strength and specificity of the intended claims, study designs may incorporate randomization, appropriate control conditions, and blinding where feasible, along with validated instrumentation capable of generating quantitative outputs in defined units. Proper protocol development, bias mitigation, statistical planning, and data validation strengthen the reliability of outcomes and support the generation of competent and defensible scientific evidence proportionate to the claims being…
Read More
29 Jan 2026
By SNI Clinical Research
How Pharmacokinetics, Pharmacodynamics, and Exposure–Response Guide Safe Dose Selection 

How Pharmacokinetics, Pharmacodynamics, and Exposure–Response Guide Safe Dose Selection 

Clinical Pharmacology, , , , , , , ,
Understanding how a health product behaves in the body, and how the body responds in return, is central to developing safe, effective, and scientifically justified therapies. Pharmacokinetics (PK) and pharmacodynamics (PD) are the disciplines that define this relationship. PK explains how much of a product reaches systemic circulation and how long it remains there, while PD explains the biological and clinical effects produced by that exposure. Together, PK and PD form the quantitative foundation that supports dose selection, clinical study design, exposure–response evaluation, and regulatory decision making.  As treatment modalities become more advanced, delivery technologies evolve, and regulators place increasing…
Read More
18 Dec 2025
By SNI Clinical Research
Skincare Clinical Studies in Canada and the United States: A Practical Guide

Skincare Clinical Studies in Canada and the United States: A Practical Guide

Clinical Research Insights, , , , , , , ,
Skincare brands today face increasing pressure to substantiate product performance and safety with real human-based evidence. As both Canadian and US markets become more evidence oriented, well-designed clinical studies are now essential for substantiating claims, satisfying regulators, and building market credibility. In this guide you will learn how clinical programs are structured, how endpoints are selected, and how regulatory frameworks in Canada and the United States affect design, execution, and commercial application of skincare research. What Are Skincare Clinical Studies and Why They Are ImportantWhy Clinical Evidence Matters for Regulatory and Commercial SuccessCommon Product Categories in Skincare Clinical StudiesCosmetic and…
Read More